Title and Organization:
David Carmel is head of immunotherapy for Atara Biotherapeutics. He was formerly co-founder and principal of Carmel Asset Management, an investment partnership where he leads all life sciences investments. Previously, he led all corporate development efforts for StemCyte, a cell therapeutics company. In 2004, he worked on the California Stem Cell and Cure Initiative that was approved by voters for $3 billion in research funds. Prior to that campaign, he worked in the top U.S strategy group at Pfizer. In 2002, Carmel was selected as a White House Fellow and was awarded the Secretary's Honor Award, the Treasury Department's highest honor. While in college, he co-founded Jumpstart a national nonprofit organization dedicated to helping every child in America enter school prepared to succeed. Since 1994, Jumpstart has trained nearly 25,000 college students and community volunteers to transform the lives of more than 42,000 preschool children nationwide. He is a founding board member of the New York Stem Cell Foundation, a board member for Jumpstart, a member of the New York State Spinal Cord Injury Research Board. David earned a B.A. degree, magna cum laude, from Harvard and an MBA from the Stanford Graduate School of Business. David is a 2006 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.